BACKGROUND Fibrinolytic therapy is the standard therapeutic method for patients with acute myocardial infarction (AMI). This study endeavored to assess the delay in arrival to the emergency department and door to needle time for thrombolytic therapy. METHODS This study was conducted on 80 patients with AMI whom referred to our clinic from January 2009 to January 2010. We measured time of arri...

In management of STEMI, time to treatment is critical. PCI is always better than thrombolytic therapy. According to ACC/AHA guidelines, door to balloon time for PCI should be less than 120 minutes. However, according to data from MITI trial if the patient is seen within 70 minutes of onset of symptoms, prehospital fibrinolytic therapy is very useful and is associated with better outcomes. Even ...

ST-segment–elevation myocardial infarction (STEMI) presents a true medical emergency, where the relationship between treatment (reperfusion) and mortality is measured in minutes. Fortunately, when administered early in properly selected patients, both fibrinolytic therapy and primary percutaneous coronary intervention (PCI) have been associated with significant reductions in mortality.1,2 Unfor...

Semi-invasive aspergillosis is a rare disease leading to severe complications even in fully immunocompetent patients. The therapeutic role of systemic and intrapleural antifungal agents remains not well known. We report herein the case of a 54-year-old woman who developed Aspergillus empyema invading the thoracic wall and subcutaneous tissues after completion pneumonectomy for aspergilloma. She...

Consultant physicians and cardiologists were surveyed early in 1987 and 1989 to document the management policies for the treatment of acute myocardial infarction in United Kingdom hospitals and to assess the influence of major clinical trials on these policies. The response rate to both these surveys was high (84% (1178 physicians) in 1987 and 76% (982 physicians) in 1989). The percentage of ph...

Thromboembolic events are potential complications of neurointerventional procedures. The mainstay of therapy for these complications is both supportive therapy and the use of fibrinolytic agents. In some cases, the occluding clot seems to be resistant to fibrinolytic or anti-platelet agents. We herein report our successful attempt at clot removal by using a microsnare to mechanically capture an...

OBJECTIVE Local recurrence remains a major problem in the treatment of malignant pleural mesothelioma. The aim of the underlying study was to establish a standardised local recurrence model in rats which enables to study different intrapleural therapies. MATERIALS AND METHODS Fifty microlitre containing 1 x 10(6) cells of a syngeneic rat malignant mesothelioma cell line (II-45), established f...

Fibrinolytic therapy has an expanding role in the treatment of many thromboembolic disorders. Four fibrinolytic drugs are currently marketed: streptokinase, anisoylated plasminogen-streptokinase activator complex, urokinase, and recombinant human tissue-type plasminogen activator. All 4 of these drugs activate the fibrinolytic system by converting plasminogen to the active enzyme, plasmin. Plas...

Nearly two decades after clinical trials established that fibrinolytic therapy for acute myocardial infarction preserves left ventricular function and reduces mortality, there is evidence that mechanical reperfusion therapy is superior in reducing the rates of death, reinfarction, intracranial bleeding, reocclusion of the infarct-related artery, and recurrent ischemia. Initially introduced as a...

Incidence Etiology and Pathogenesis Diagnostic Approaches Clinical Manifestations Imaging Techniques Diagnostic Thoracentesis Closed Pleural Biopsy Medical Thoracoscopy Bronchoscopy Surgical Biopsy Treatment Indications and Contraindications Therapeutic Thoracentesis Chemical Pleurodesis Doxycycline Bleomycin Talc Pleurodesis Talc Poudrage Talc Slurry Treatment of Pleurodesis Failure Other Trea...